Metagenomi Therapeutics IncMGX
Price$1.10Intrinsic value$1.5239% above price

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $22.3M-57.3% YoYTTM through 31 Mar 2026
Net Income -$93.5MTTM through 30 Jun 2026
Free Cash Flow -$85.8MTTM through 30 Jun 2026

Margins

Current
Gross Margin78.9%
EBITDA Margin-426.8%
Operating Margin-380.9%
Net Margin-418.5%

Returns

-55.4%ROE
-39.7%ROA

Balance Sheet Health

Debt / Equity0.26x
Current Ratio7.22x
Net Debt-$120.1Mnet cash position
Cash & Equivalents$39M

Quality Metrics

Altman Z-Score-3.60
Piotroski F-Score1 / 9
FCF Margin-384.2%
Earnings-Beat Rate25.0%

Multi-Year Trend

Revenue
'23'24'25
FY2025: $25.2M
Diluted EPS-$2.49TTM
'23'24'25
FY2025: $-2.36

Dividend

No dividend

Capital Allocation

Capex Intensity1.4%

Segment Performance

No segment data available.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.